PhytoGaia, a supplier specializing in palm phytonutrients, announced the approval of a new clinical study on whether a combination of squalene and tocotrienols, marketed as STGaia, can influence measures of cellular health and biological aging.

The new study will follow recent findings from a clinical trial which found that the company’s tocotrienols ingredient, TocoGaia, was associated with significant improvements in measures of quality of life, greater antioxidant status, reduced inflammatory markers, and greater maintenance of telomerase activity.

The upcoming randomized, double-blind, placebo-controlled clinical trial will involve healthy participants between the ages of 50 and 75, over a period of six months. The primary outcome will be STGaia’s effects on telomere length and telomerase activity, two measures of biological aging. Secondary endpoints will include NAD+/NADH ratio, ATP levels, antioxidant enzyme activity, inflammation markers like CRP and TNF-a, and the expression of genes tied to longevity, like SIRT1, CDKN2A/p16, and IGF-1.

“With the recent publication of a clinical study on full-spectrum palm tocotrienols in healthy aging, this new trial with STGaia marks an exciting next chapter in our ongoing exploration of palm phytonutrients and their role in cellular health and longevity,” said Bryan See, vice president of PhytoGaia. “It underscores our continued commitment to human clinical research in aging and longevity. We’re proud to collaborate once again with Monash University, one of the world’s top academic institutions, as we investigate STGaia’s potential in preserving telomere length and supporting genomic integrity at the cellular level.”

“This study represents an exciting opportunity to investigate how our local, naturally-derived bioactives such as tocotrienols and squalene may modulate cellular aging pathways,” said Ammu Radhakrishnan, principal investigator and professor at Monash University. “We look forward to this collaboration to explore the potential of STGaia to support genomic stability, telomere health, and overall longevity through a rigorous, science-based approach.”

“Building on current scientific findings, we believe that the synergy between tocotrienols and plant squalene represents a novel approach to healthy aging,” said Ariati Aris, PhD, scientific affairs specialist at PhytoGaia. “This trial will deepen our understanding of the mechanisms behind STGaia’s multi-targeted benefits and further strengthen its clinical validation in longevity and healthy lifespan solutions.”